Monday, August 31, 2026

Albemarle Stock Bearish Momentum With A 10% Fall At Session Start Today

ViaNews Editorial Team

February 17, 2023

Albemarle Stock Bearish Momentum With A 10% Fall At Session Start Today

(VIANEWS) - Shares of Albemarle (NYSE: ALB) fell by a staggering 10.55% to $255.50 at 10:15 EST on Friday, after five consecutive sessions in a row of gains. NYSE is dropping 0.89% to $15,873.78, after three sequential sessions in a row of losses. This seems, as yet, a somewhat bearish trend exchanging session today.

Albemarle's last close was $285.62, 14.63% under its 52-week high of $334.55.

About Albemarle

Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Lithium, Bromine, and Catalysts. The Lithium segment offers lithium compounds, including lithium carbonate, lithium hydroxide, lithium chloride, and lithium specialties; and reagents, such as butyllithium and lithium aluminum hydride for use in lithium batteries for consumer electronics and electric vehicles, high performance greases, thermoplastic elastomers for car tires, rubber soles, plastic bottles, catalysts for chemical reactions, organic synthesis processes in the areas of steroid chemistry and vitamins, life sciences, pharmaceutical industry, and other markets. It also provides cesium products for the chemical and pharmaceutical industries; zirconium, barium, and titanium products for pyrotechnical applications that include airbag initiators; technical services for the handling and use of reactive lithium products; and lithium-containing by-products recycling services. The Bromine segment offers bromine and bromine-based fire safety solutions; specialty chemicals, including elemental bromine, alkyl and inorganic bromides, brominated powdered activated carbon, and other bromine fine chemicals for use in chemical synthesis, oil and gas well drilling and completion fluids, mercury control, water purification, beef and poultry processing, and other industrial applications; and other specialty chemicals, such as tertiary amines for surfactants, biocides, and disinfectants and sanitizers. The Catalysts segment provides hydroprocessing, isomerization, and akylation catalysts; fluidized catalytic cracking catalysts and additives; and organometallics and curatives. The company serves the energy storage, petroleum refining, consumer electronics, construction, automotive, lubricants, pharmaceuticals, and crop protection markets. Albemarle Corporation was founded in 1887 and is headquartered in Charlotte, North Carolina.

Earnings Per Share

As for profitability, Albemarle has a trailing twelve months EPS of $3.52.

PE Ratio

Albemarle has a trailing twelve months price to earnings ratio of 72.59. Meaning, the purchaser of the share is investing $72.59 for every dollar of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.66%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 91.2%, now sitting on 4.33B for the twelve trailing months.

Growth Estimates Quarters

The company's growth estimates for the current quarter and the next is 565.7% and 729.7%, respectively.

More news about Albemarle (ALB).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com